vs

Side-by-side financial comparison of COGNEX CORP (CGNX) and FOCUS UNIVERSAL INC. (FCUV). Click either name above to swap in a different company.

COGNEX CORP is the larger business by last-quarter revenue ($252.3M vs $749, roughly 336899.9× FOCUS UNIVERSAL INC.). On growth, COGNEX CORP posted the faster year-over-year revenue change (9.9% vs -99.4%). COGNEX CORP produced more free cash flow last quarter ($72.3M vs $-1.4M). Over the past eight quarters, COGNEX CORP's revenue compounded faster (9.4% CAGR vs -93.5%).

Cognex Corporation is an American manufacturer of machine vision systems, software and sensors. Cognex is headquartered in Natick, Massachusetts, USA with offices in more than 20 countries.

Universal Health Services, Inc. (UHS) is an American Fortune 500 company that provides hospital and healthcare services, based in King of Prussia, Pennsylvania. In 2024, UHS reported total revenues of $15.8 billion.

CGNX vs FCUV — Head-to-Head

Bigger by revenue
CGNX
CGNX
336899.9× larger
CGNX
$252.3M
$749
FCUV
Growing faster (revenue YoY)
CGNX
CGNX
+109.3% gap
CGNX
9.9%
-99.4%
FCUV
More free cash flow
CGNX
CGNX
$73.7M more FCF
CGNX
$72.3M
$-1.4M
FCUV
Faster 2-yr revenue CAGR
CGNX
CGNX
Annualised
CGNX
9.4%
-93.5%
FCUV

Income Statement — Q4 2025 vs Q4 2025

Metric
CGNX
CGNX
FCUV
FCUV
Revenue
$252.3M
$749
Net Profit
$32.7M
Gross Margin
65.7%
-6912.1%
Operating Margin
14.0%
-119973.6%
Net Margin
12.9%
Revenue YoY
9.9%
-99.4%
Net Profit YoY
15.2%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CGNX
CGNX
FCUV
FCUV
Q4 25
$252.3M
$749
Q3 25
$276.9M
$28.7K
Q2 25
$249.1M
$35.3K
Q1 25
$216.0M
$190.3K
Q4 24
$229.7M
$133.2K
Q3 24
$234.7M
$74.2K
Q2 24
$239.3M
$11.2K
Q1 24
$210.8M
$179.5K
Net Profit
CGNX
CGNX
FCUV
FCUV
Q4 25
$32.7M
Q3 25
$17.7M
$-1.2M
Q2 25
$40.5M
$-1.5M
Q1 25
$23.6M
$-1.3M
Q4 24
$28.3M
Q3 24
$29.6M
$1.4M
Q2 24
$36.2M
$-1.4M
Q1 24
$12.0M
$-1.3M
Gross Margin
CGNX
CGNX
FCUV
FCUV
Q4 25
65.7%
-6912.1%
Q3 25
67.6%
-5.6%
Q2 25
67.4%
-35.1%
Q1 25
66.8%
16.1%
Q4 24
68.7%
-95.4%
Q3 24
67.9%
42.7%
Q2 24
69.6%
Q1 24
67.3%
50.3%
Operating Margin
CGNX
CGNX
FCUV
FCUV
Q4 25
14.0%
-119973.6%
Q3 25
20.9%
-4114.4%
Q2 25
17.4%
-4366.7%
Q1 25
12.1%
-668.3%
Q4 24
13.4%
-1507.4%
Q3 24
13.4%
-2353.8%
Q2 24
16.1%
-10965.3%
Q1 24
6.7%
-676.3%
Net Margin
CGNX
CGNX
FCUV
FCUV
Q4 25
12.9%
Q3 25
6.4%
-4065.6%
Q2 25
16.3%
-4261.7%
Q1 25
10.9%
-657.7%
Q4 24
12.3%
Q3 24
12.6%
1942.9%
Q2 24
15.1%
-12151.6%
Q1 24
5.7%
-732.9%
EPS (diluted)
CGNX
CGNX
FCUV
FCUV
Q4 25
$0.20
Q3 25
$0.10
Q2 25
$0.24
Q1 25
$0.14
$-0.17
Q4 24
$0.17
$-4.57
Q3 24
$0.17
$0.02
Q2 24
$0.21
$-0.02
Q1 24
$0.07
$-0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CGNX
CGNX
FCUV
FCUV
Cash + ST InvestmentsLiquidity on hand
$262.9M
$8.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.5B
$2.6M
Total Assets
$2.0B
$8.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CGNX
CGNX
FCUV
FCUV
Q4 25
$262.9M
$8.0M
Q3 25
$245.9M
$454.4K
Q2 25
$179.3M
$1.2M
Q1 25
$143.7M
$2.2M
Q4 24
$186.1M
$3.6M
Q3 24
$197.1M
$5.4M
Q2 24
$176.6M
$40.6K
Q1 24
$138.9M
$114.1K
Stockholders' Equity
CGNX
CGNX
FCUV
FCUV
Q4 25
$1.5B
$2.6M
Q3 25
$1.5B
$174.8K
Q2 25
$1.5B
$845.6K
Q1 25
$1.4B
$1.9M
Q4 24
$1.5B
$3.2M
Q3 24
$1.6B
$5.4M
Q2 24
$1.5B
$1.2M
Q1 24
$1.5B
$2.4M
Total Assets
CGNX
CGNX
FCUV
FCUV
Q4 25
$2.0B
$8.9M
Q3 25
$2.0B
$880.4K
Q2 25
$2.0B
$1.7M
Q1 25
$1.9B
$2.7M
Q4 24
$2.0B
$4.1M
Q3 24
$2.1B
$6.2M
Q2 24
$2.0B
$4.9M
Q1 24
$2.0B
$5.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CGNX
CGNX
FCUV
FCUV
Operating Cash FlowLast quarter
$74.9M
$-1.4M
Free Cash FlowOCF − Capex
$72.3M
$-1.4M
FCF MarginFCF / Revenue
28.7%
-186175.6%
Capex IntensityCapex / Revenue
1.0%
105.2%
Cash ConversionOCF / Net Profit
2.29×
TTM Free Cash FlowTrailing 4 quarters
$236.8M
$-5.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CGNX
CGNX
FCUV
FCUV
Q4 25
$74.9M
$-1.4M
Q3 25
$87.5M
$-1.1M
Q2 25
$42.6M
$-1.4M
Q1 25
$40.5M
$-1.2M
Q4 24
$51.4M
$-997.9K
Q3 24
$56.3M
$-1.9M
Q2 24
$27.8M
$-829.9K
Q1 24
$13.6M
$-892.1K
Free Cash Flow
CGNX
CGNX
FCUV
FCUV
Q4 25
$72.3M
$-1.4M
Q3 25
$86.0M
$-1.1M
Q2 25
$40.4M
$-1.4M
Q1 25
$38.0M
$-1.2M
Q4 24
$49.3M
$-1.0M
Q3 24
$51.9M
$-1.9M
Q2 24
$23.3M
$-834.6K
Q1 24
$9.6M
$-897.1K
FCF Margin
CGNX
CGNX
FCUV
FCUV
Q4 25
28.7%
-186175.6%
Q3 25
31.1%
-3705.4%
Q2 25
16.2%
-4047.4%
Q1 25
17.6%
-653.6%
Q4 24
21.5%
-753.3%
Q3 24
22.1%
-2614.6%
Q2 24
9.7%
-7428.8%
Q1 24
4.5%
-499.8%
Capex Intensity
CGNX
CGNX
FCUV
FCUV
Q4 25
1.0%
105.2%
Q3 25
0.5%
7.8%
Q2 25
0.9%
4.8%
Q1 25
1.2%
12.3%
Q4 24
0.9%
4.1%
Q3 24
1.9%
4.7%
Q2 24
1.9%
41.8%
Q1 24
1.9%
2.8%
Cash Conversion
CGNX
CGNX
FCUV
FCUV
Q4 25
2.29×
Q3 25
4.95×
Q2 25
1.05×
Q1 25
1.72×
Q4 24
1.81×
Q3 24
1.90×
-1.34×
Q2 24
0.77×
Q1 24
1.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons